Liraglutide and Renal Outcomes in Type 2 Diabetes

In a randomized, controlled trial, liraglutide (a glucagon-like peptide 1 receptor agonist) or placebo was added to usual care in patients with type 2 diabetes. In secondary analyses, rates of development and progression of diabetic kidney disease were lower with liraglutide.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	NEW ENGLAND JOURNAL OF MEDICINE 2017-08, Vol.377 (9), p.839-848
Hauptverfasser:	Mann, Johannes F.E, Ørsted, David D, Brown-Frandsen, Kirstine, Marso, Steven P, Poulter, Neil R, Rasmussen, Søren, Tornøe, Karen, Zinman, Bernard, Buse, John B
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - prevention & control Aged Albuminuria - prevention & control Antidiabetics Cardiovascular diseases Cerebral infarction Clinical outcomes Creatinine Creatinine - blood Death Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy Diabetic Nephropathies - mortality Diabetic Nephropathies - prevention & control Double-Blind Method Drug therapy End-stage renal disease Female Follow-Up Studies Glomerular Filtration Rate Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide 1 - agonists Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Intention to Treat Analysis Kidney diseases Kidney Failure, Chronic - prevention & control Kidney transplantation Liraglutide - adverse effects Liraglutide - therapeutic use Long-term effects Male Middle Aged Myocardial infarction Patients Risk factors Stroke
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!